A Phase 2 interventional study of Liraglutide Pen Injector and Saline Injections in Type 1 Diabetes and Type 2 Diabetes, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 25 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Mayo Clinic · Phase 2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing liraglutide in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Liraglutide · Diabetes Mellitus, Type 1.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is one of 10 in phase 2, and was the 32nd registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →2 of the 32 studies testing liraglutide in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:
Second Xiangya Hospital of Central South University · Sites in China
Ages 18+
By country, each count listing its studies:
Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 25 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14 · Phase 3 12 · Phase 4 3
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 38 across the 32 interventional studies. Of the 25 that completed or were terminated, 12 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 32 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic: 3 open now, 3 under way, none of them phase 3. Of 11 finished, 4 (36%) have results posted.
Among the 16 studies in Diabetes Mellitus, Type 1 by Mayo Clinic, this one is the 2nd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is the only one in phase 2, and was the 15th registered.
Mayo Clinic’s Diabetes Mellitus, Type 1 studies by the year they started, since 1995.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing liraglutide in Diabetes Mellitus, Type 1, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Mayo Clinic’s 16 in Diabetes Mellitus, Type 1:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets. However, its regulation is at present unknown. There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell3. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ in Type 1 diabetes (T1DM) compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
The investigators recently demonstrated that blockade of Glucagon-Like Peptide-1's (GLP-1) receptor (GLP1R) results in changes in islet function without changes in circulating GLP-1. This supports other evidence (rodents and humans) that through the (inducible) expression of a prohormone convertase (PC-1/3), the α-cell can process proglucagon to intact GLP-15,6. 'Islet' or 'pancreatic' GLP-1 acts in a paracrine fashion to regulate insulin (basal and 1st phase) and glucagon secretion. These effects are more pronounced in people with early type 2 diabetes (T2DM) in keeping with increased expression of PC-1/3 and GLP-1 that is observed in diabetic islets.
There is evidence that α-cell proglucagon processing is subject to paracrine regulation by the β-cell. β-cell secretion of the signaling peptide 14-3-3-Zeta is decreased by GLP1R agonism (Fig.1), stimulating α-cell production of GLP-1. This is a testable hypothesis in humans; people with type 1 diabetes (T1DM) have dysregulated glucagon secretion and evidence of islet GLP-1. It is unclear if the effects of GLP1R agonism on islet GLP-1 differ compared to T2DM. This experiment will examine the effect of glycemic control ± a GLP1R agonist on islet GLP-1 in people with (T2DM) and without (T1DM) β-cells.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive syringes loaded with saline to self-administer daily during the intervention phase
Other: Saline Injections
Subjects will receive 0.6mg Liraglutide syringes to self-administer daily during the intervention phase
Drug: Liraglutide Pen Injector
Subjects will receive syringes loaded with saline to self-administer daily during the intervention phase
Other: Saline Injections
Subjects will receive 0.6mg Liraglutide syringes to self-administer daily during the intervention phase
Drug: Liraglutide Pen Injector
Liraglutide 0.6mg
Also known as: Liraglutide
Saline in syringes to serve as placebo for single blind study
Also known as: Placebo
Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during fasting (-30 to 0 min) of each study day.
Time frame: The change in fasting glucagon secretion rate (saline vs. exendin 9-39) in the baseline study will be compared with the change in fasting glucagon secretion rate (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)
Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia before and after liraglutide
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during hyperglycemia (150 to 180 min) of each study day.
Time frame: The change in glucagon secretion rate during hyperglycemia (saline vs. exendin 9-39) in the baseline study will be compared with the change (saline vs. exendin 9-39) after 30 days of treatment with liraglutide (post-liraglutide)
Effect of exendin 9-39 on fasting glucagon secretion rate in people with type 1 diabetes vs type 2 diabetes
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during fasting (-30 to 0 minutes) during the baseline studies
Time frame: The change in fasting glucagon secretion (saline vs. exendin 9-39) in the baseline studies will be compared in people with type 1 diabetes vs type 2 diabetes
Effect of exendin 9-39 on glucagon secretion rate during hyperglycemia in people with type 1 diabetes vs type 2 diabetes
Glucagon secretion rate will be estimated by deconvolution from glucagon concentrations during hyperglycemia (150 to 180 minutes) during the baseline studies
Time frame: The change in glucagon secretion during hyperglycemia (saline vs. exendin 9-39) in the baseline studies will be compared in people with type 1 diabetes vs type 2 diabetes
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Oct 2028, 36 months after the start.
Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 36 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liraglutide